<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651518</url>
  </required_header>
  <id_info>
    <org_study_id>P160906J</org_study_id>
    <secondary_id>2017-000519-18</secondary_id>
    <nct_id>NCT03651518</nct_id>
  </id_info>
  <brief_title>Personalized Therapies in Inflammatory Complex Disease</brief_title>
  <acronym>PIMOC</acronym>
  <official_title>Personalized Targeted Therapies in Inflammatory Complex Multi Organ Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory diseases may display atypical features making such patients impossible to
      classify. Management of these cases in daily practice cannot rely on the results of clinical
      trials nor on guidelines. DNA and RNA mapping have become major tools to understand and
      sometimes direct the treatment strategy in oncology. This study aims to test whether a
      precise analysis of molecular pathways in inflammatory, non classified diseases, can
      constitute a predictive tool of therapeutic efficiency
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IIb study. The main objective of this study is to evaluate the efficacy of
      targeted treatments in patients displaying a non-classified, severe and resistant
      inflammatory disease. Targeted treatments for each patient will have been selected through an
      algorithm based on molecular analysis of specific altered inflammatory signaling pathway.

      Treatments consist in targeted therapies approved in other indications (Kineret®, Humira®,
      Stelara®, Cosentyx®, Roactemra® and Rituximab®) that will be given once selected using
      molecular analysis and decision making procedure by the Scientific committee.

      For each patient, one targeted treatment will be administered according to the SmPC procedure
      for a treatment period of 6 months.

      Primary efficacy endpoint:

      Response will be assessed at month 6 with a composite endpoint defined as improvement of at
      least 2 of the 3 following parameters:

        -  50% improvement of the systemic activity assessed by the clinician following a visual
           analog scale (0-10 mm),

        -  and/or 50% improvement of cutaneous activity assessed by the involved skin surface area,

        -  and/or 50% decrease or normalisation of biological markers of inflammation (either CRP,
           ESR or fibrin).

      An independent adjudication committee blinded to the treatment received, will review primary
      endpoint for all patients based on clinical files and standardized photographs, to validate
      the response.

      Other secondary criteria will be assessed. Overall, this study will require a molecular
      analysis done on patient's tissue, the final aim being to evaluate efficiency and tolerance
      of targeted treatments chosen in a personalized analysis when classification is impossible.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite clinico-biological evaluation</measure>
    <time_frame>6 months</time_frame>
    <description>Response will be assessed at month 6 with a composite endpoint defined as improvement of at least of 2 of the 3 following parameters:
50% improvement of the systemic activity assessed by the clinician following a visual analog scale (0-10), where clinician will be asked the following question: &quot;Please indicate, according to your clinical experience and taking into account all systemic manifestations, the level of disease activity in this patient using the following scale:&quot;
and/or 50% improvement of cutaneous activity assessed by the involved skin surface area (according the rule of 9%). Standardised skin pictures will be done in order to centrally review cutaneous response.
and/or 50% decrease or normalisation of biological markers of inflammation (either CRP, ESR or fibrin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Infections</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver cell count toxicities</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney cell count toxicities</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood cell count toxicities</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate tolerance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment (PGA)</measure>
    <time_frame>1 month,</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment (PGA)</measure>
    <time_frame>3 months,</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Physician Global Assessment (PGA)</measure>
    <time_frame>6 months,</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in continuous PGA</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in continuous PGA</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in British Isles Lupus Assessment Group (BILAG)</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in British Isles Lupus Assessment Group (BILAG)</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in British Isles Lupus Assessment Group (BILAG)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in British Isles Lupus Assessment Group (BILAG)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Lupus Erythematosus Responder Index (SRI)</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Lupus Erythematosus Responder Index (SRI)</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Lupus Erythematosus Responder Index (SRI)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systemic Lupus Erythematosus Responder Index (SRI)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cutaneous Lupus Disease Area and Severity Index (CLASI)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Health Survey (SF36)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate clinical efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CRP</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR (Erythrocyte sedimentation rate)</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR (Erythrocyte sedimentation rate)</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR (Erythrocyte sedimentation rate)</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR (Erythrocyte sedimentation rate)</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ESR (Erythrocyte sedimentation rate)</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrin</measure>
    <time_frame>1 month,</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrin</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrin</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrin</measure>
    <time_frame>9 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fibrin</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens</measure>
    <time_frame>1 month</time_frame>
    <description>to evaluate targeted biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens</measure>
    <time_frame>3 months</time_frame>
    <description>to evaluate targeted biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens</measure>
    <time_frame>6 months</time_frame>
    <description>to evaluate targeted biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decreased in serum increased cytokines, in selected RNA in peripheral blood and skin specimens</measure>
    <time_frame>12 months</time_frame>
    <description>to evaluate targeted biological efficiency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RNA analysis of targeted cytokines and RNA sequencing</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Inflammatory Disease</condition>
  <condition>Autoimmune Diseases</condition>
  <arm_group>
    <arm_group_label>Kineret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stelara</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cosentyx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Roactemra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kineret</intervention_name>
    <description>100 mg, once/day sc 6 months</description>
    <arm_group_label>Kineret</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humira</intervention_name>
    <description>40 mg/15 days sc 6 months</description>
    <arm_group_label>Humira</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stelara</intervention_name>
    <description>45 mg/12 weeks sc, 6 months</description>
    <arm_group_label>Stelara</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cosentyx</intervention_name>
    <description>300mg sc every week for 1 month, then 300 mg/month sc for 5 months</description>
    <arm_group_label>Cosentyx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roactemra</intervention_name>
    <description>480 mg/perf/4 weeks 6 months</description>
    <arm_group_label>Roactemra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>2 sessions of 1000 mg at inclusion and 15 days after inclusion</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (men or women) aged 18 years old and over

          -  Patients presenting inflammatory non classified disease targeting at least 2 organs
             involvement: skin, lymph nodes, hemopoietic system, joints, digestive tract. Skin
             involvement is mandatory in order to be able to compare involved and non-involved
             tissue

          -  Signed informed consent

        The disease should be considered as non-classified despite classical and adapted
        investigations and evaluation through expert committee meeting The disease alters
        significantly quality of life using SF36 assessment: score less than 30 The disease has
        been resistant to at least two prior lines of treatment

        Exclusion Criteria:

          -  Patients presenting disease which is not featured by lesional and healthy skin areas,
             easy to biopsy

          -  Patients refusing biopsies

          -  Pregnancy

          -  Breastfeeding

          -  Patients presenting disease needing urgent therapeutic measures

          -  Patients without health insurance or social security

          -  Participation in another trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selim ARACTINGI, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selim ARACTINGI, PhD</last_name>
    <phone>+ 33 1 58 41 19 88</phone>
    <email>selim.aractingi@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christelle AUGER</last_name>
    <phone>+ 33 1 58 41 11 86</phone>
    <email>christelle.auger@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>selim ARACTINGI, PhD</last_name>
      <phone>+ 33 1 58 41 19 88</phone>
      <email>selim.aractingi@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>June 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Personalized treatment</keyword>
  <keyword>Inflammatory diseases</keyword>
  <keyword>auto-inflammatory diseases</keyword>
  <keyword>auto-immune diseases</keyword>
  <keyword>Targeted treatments</keyword>
  <keyword>skin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

